shutterstock_1524542537_michael_vi

Michael Vi / Shutterstock.com

9 February 2021AmericasRory O'Neill

J&J reaches $6m settlement over counterfeit surgical tools

Johnson & Johnson (J&J) has settled its case against Advanced Inventory Management (AIM), trading as eSutures, which it accused of distributing counterfeit and contaminated surgical tools.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Federal Circuit backs PTAB in Johnson & Johnson patent appeal

4 January 2017 The US Court of Appeals for the Federal Circuit has affirmed a Patent Trial and Appeal Board decision that said patent claims owned by Ethicon, a subsidiary of Johnson & Johnson (J&J), are invalid.

Surgical device maker hit with $10m damages in stapler patent dispute

20 October 2022 Lawsuit centred on methods for stapling tissue during surgery | Delaware federal jury found in favour of Rex Medical.

article

Report: Market for anti-counterfeit drugs packaging to hit $191bn by 2030

24 January 2023 New study examines industry by product, application and region | China, Germany and India predicted to see the largest growth.

More on this story

article

Report: Market for anti-counterfeit drugs packaging to hit $191bn by 2030

24 January 2023 New study examines industry by product, application and region | China, Germany and India predicted to see the largest growth.

Surgical device maker hit with $10m damages in stapler patent dispute

20 October 2022 Lawsuit centred on methods for stapling tissue during surgery | Delaware federal jury found in favour of Rex Medical.

Federal Circuit backs PTAB in Johnson & Johnson patent appeal

4 January 2017 The US Court of Appeals for the Federal Circuit has affirmed a Patent Trial and Appeal Board decision that said patent claims owned by Ethicon, a subsidiary of Johnson & Johnson (J&J), are invalid.

More on this story

article

Report: Market for anti-counterfeit drugs packaging to hit $191bn by 2030

24 January 2023 New study examines industry by product, application and region | China, Germany and India predicted to see the largest growth.

Surgical device maker hit with $10m damages in stapler patent dispute

20 October 2022 Lawsuit centred on methods for stapling tissue during surgery | Delaware federal jury found in favour of Rex Medical.

Federal Circuit backs PTAB in Johnson & Johnson patent appeal

4 January 2017 The US Court of Appeals for the Federal Circuit has affirmed a Patent Trial and Appeal Board decision that said patent claims owned by Ethicon, a subsidiary of Johnson & Johnson (J&J), are invalid.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Kathi Vidal to leave USPTO ahead of incoming Trump administration

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

Teva fights for re-listing of inhaler patents at US appeals court

CRISPR patents revoked following Nobel Prize winners’ withdrawal

White & Case hires experienced litigator from A&O Shearman

President Trump 2.0: Five major areas to watch